Biological Properties of Transition Metal Complexes with Metformin and Its Analogues

Pharmaceuticals (Basel). 2022 Apr 6;15(4):453. doi: 10.3390/ph15040453.

Abstract

Metformin is a widely prescribed medication for the treatment and management of type 2 diabetes. It belongs to a class of biguanides, which are characterized by a wide range of diverse biological properties, including anticancer, antimicrobial, antimalarial, cardioprotective and other activities. It is known that biguanides serve as excellent N-donor bidentate ligands and readily form complexes with virtually all transition metals. Recent evidence suggests that the mechanism of action of metformin and its analogues is linked to their metal-binding properties. These findings prompted us to summarize the existing data on the synthetic strategies and biological properties of various metal complexes with metformin and its analogues. We demonstrated that coordination of biologically active biguanides to various metal centers often resulted in an improved pharmacological profile, including reduced drug resistance as well as a wider spectrum of activity. In addition, coordination to the redox-active metal centers, such as Au(III), allowed for various activatable strategies, leading to the selective activation of the prodrugs and reduced off-target toxicity.

Keywords: antibacterial; anticancer; antidiabetic; antifungal; antimalarial; biguanides; gold; lanthanides; metal complexes; metformin; phenformin; prodrugs; transition metals.

Publication types

  • Review